BACKGROUND: Previously, herpes zoster (HZ) was found to occur at a higher rate in the HIV population than the general population. However, there are limited data about the incidence, risk factors, and clinical outcomes of HZ in the current antiretroviral therapy (ART) era. METHODS: We identified HZ episodes in an urban HIV clinic cohort between 2002 and 2009. Three controls were matched to each case, and conditional logistic regression was used to assess for risk factors associated with incident HZ cases. Logistic regression was used to assess for factors associated with complicated HZ. RESULTS: One hundred eighty-three new HZ cases were identified in 4353 patients with 19,752 person-years (PY) of follow-up--an incidence rate 9.3/1000 PY. Cases were majority men (62%) and African American (75%), with a mean age of 39 years (interquartile range, 32-44 years). Fifty patients (28%) had complicated HZ with 12% developing postherpetic neuralgia. In multivariate regression, factors associated with the increased risk of HZ were having started ART within 90 days of the episode [adjusted odds ratio (AOR), 4.02; 95% confidence interval (CI), 1.31 to 12.41], having a viral load of >400 copies per milliliter (AOR, 1.49; 95% CI, 1.00 to 2.24), and having a CD4 <350 cells per cubic millimeter (AOR, 2.46; 95% CI, 1.42 to 4.23) or 350 to 500 cells per cubic millimeter (AOR, 2.02; 95% CI, 1.14 to 3.57) as compared with CD4 >500 cells per cubic millimeter. CONCLUSIONS: The incidence of HZ is lower than previously reported in HIV cohorts but remains higher than the general population. Over one fourth of patients developed complicated HZ, which is remarkable given the young age of our population. Risk factors for HZ include markers of poor immune function, suggesting that appropriate ART may reduce the burden of HZ in this population.
BACKGROUND: Previously, herpes zoster (HZ) was found to occur at a higher rate in the HIV population than the general population. However, there are limited data about the incidence, risk factors, and clinical outcomes of HZ in the current antiretroviral therapy (ART) era. METHODS: We identified HZ episodes in an urban HIV clinic cohort between 2002 and 2009. Three controls were matched to each case, and conditional logistic regression was used to assess for risk factors associated with incident HZ cases. Logistic regression was used to assess for factors associated with complicated HZ. RESULTS: One hundred eighty-three new HZ cases were identified in 4353 patients with 19,752 person-years (PY) of follow-up--an incidence rate 9.3/1000 PY. Cases were majority men (62%) and African American (75%), with a mean age of 39 years (interquartile range, 32-44 years). Fifty patients (28%) had complicated HZ with 12% developing postherpetic neuralgia. In multivariate regression, factors associated with the increased risk of HZ were having started ART within 90 days of the episode [adjusted odds ratio (AOR), 4.02; 95% confidence interval (CI), 1.31 to 12.41], having a viral load of >400 copies per milliliter (AOR, 1.49; 95% CI, 1.00 to 2.24), and having a CD4 <350 cells per cubic millimeter (AOR, 2.46; 95% CI, 1.42 to 4.23) or 350 to 500 cells per cubic millimeter (AOR, 2.02; 95% CI, 1.14 to 3.57) as compared with CD4 >500 cells per cubic millimeter. CONCLUSIONS: The incidence of HZ is lower than previously reported in HIV cohorts but remains higher than the general population. Over one fourth of patients developed complicated HZ, which is remarkable given the young age of our population. Risk factors for HZ include markers of poor immune function, suggesting that appropriate ART may reduce the burden of HZ in this population.
Authors: S P Buchbinder; M H Katz; N A Hessol; J Y Liu; P M O'Malley; R Underwood; S D Holmberg Journal: J Infect Dis Date: 1992-11 Impact factor: 5.226
Authors: J Veenstra; A Krol; R M van Praag; P H Frissen; P T Schellekens; J M Lange; R A Coutinho; J T van der Meer Journal: AIDS Date: 1995-10 Impact factor: 4.177
Authors: Robert W Johnson; Marie-José Alvarez-Pasquin; Marc Bijl; Elisabetta Franco; Jacques Gaillat; João G Clara; Marc Labetoulle; Jean-Pierre Michel; Luigi Naldi; Luis S Sanmarti; Thomas Weinke Journal: Ther Adv Vaccines Date: 2015-07
Authors: Kate Shearer; Mhairi Maskew; Toyin Ajayi; Rebecca Berhanu; Pappie Majuba; Ian Sanne; Matthew P Fox Journal: Int J Infect Dis Date: 2014-03-25 Impact factor: 3.623
Authors: Kosuke Kawai; Claudia A Hawkins; Ellen Hertzmark; Joel M Francis; David Sando; Aisa N Muya; Nzovu Ulenga; Wafaie W Fawzi Journal: Am J Trop Med Hyg Date: 2018-01-04 Impact factor: 2.345
Authors: Laura Gilbert; Xun Wang; Robert Deiss; Jason Okulicz; Ryan Maves; Christina Schofield; Tomas Ferguson; Timothy Whitman; Karl Kronmann; Brian Agan; Anuradha Ganesan Journal: Clin Infect Dis Date: 2019-06-18 Impact factor: 9.079
Authors: Constance A Benson; Janet W Andersen; Bernard J C Macatangay; Robbie B Mailliard; Charles R Rinaldo; Sarah Read; Dawn R Bozzolo; Lynette Purdue; Cheryl Jennings; Michael C Keefer; Marshall Glesby; Pablo Tebas; Amy Falk Russell; Jason Martin; Paula Annunziato; Zoran Popmihajlov; Jeffrey L Lennox Journal: Clin Infect Dis Date: 2018-11-13 Impact factor: 9.079
Authors: Ana I Sánchez; Mary A García-Acero; Angela Paredes; Rossi Quero; Rita I Ortega; Jorge A Rojas; Daniel Herrera; Miguel Parra; Karol Prieto; Juana Ángel; Luz-Stella Rodríguez; Juan C Prieto; Manuel Franco Journal: Mol Syndromol Date: 2020-02-05
Authors: Kristine M Erlandson; Amber Streifel; Alexander R Novin; Kellie L Hawkins; Clayton Foster; Jacob Langness; Mary Bessesen; Julian Falutz; Abeer Moanna; David Looney; Scott T Johns; Joseph B Nguyen; Michael N Oxman; Myron J Levin Journal: AIDS Res Hum Retroviruses Date: 2018-05-21 Impact factor: 2.205
Authors: María D Esteban-Vasallo; M Felicitas Domínguez-Berjón; Ruth Gil-Prieto; Jenaro Astray-Mochales; Angel Gil de Miguel Journal: Hum Vaccin Immunother Date: 2014-05-07 Impact factor: 3.452